Trial Profile
Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2018
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRIVIG
- Sponsors Grifols
- 18 Sep 2014 New trial record